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n INTRODUCTION
Coronaviridae, Arteriviridae, and Roniviridae are the three families of the Nidovirales order 
[1]. The Coronavirinae  family is divided into two 
subfamilies which include the  Coronaviridae  and 
the Torovirinae. The Coronavirinae  is also divided 
into four categories by phylogenetic clustering 
which are comprising the alpha, beta, gamma 
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and delta coronaviruses [1]. The envelope and a 
non-segmented positive-sense RNA are the char-
acteristics of viruses in Nidovirales order. While all 
of these viruses possess large genomes, Corona-
virinae is considered to contain the largest RNA 
genome that is identified [1]. Family of coronavi-
ruses consists of viruses which can lead to several 
symptoms including fever, dyspnea, and pneu-
monia [2]. Coronavirus is responsible for impor-
tant public health problems that led to the global 
epidemics including severe acute respiratory syn-
drome (SARS), Middle East respiratory syndrome 
(MERS), and coronavirus disease 2019 (COV-
ID-19) [3]. Rather than SARS-CoV-1 and MERS-
Background: Since December 2019, coronavirus disease 
2019 (COVID-19) has become a major health problem 
that is spreading all over the world. Several viral infec-
tions such as SARS, MERS, and influenza have been as-
sociated with adverse pregnancy outcomes. The ques-
tion arises whether pregnant women are at greater risk 
of complications related to COVID-19 compared to 
other people What complications should we expect in 
the fetuses whose mothers were infected? 
Aims: This review aims to provide a summary of stud-
ies on symptoms of COVID-19 and the possible risks 
of COVID-19 among pregnant women, as well as com-
plications in fetuses and neonates whose mothers were 
infected with COVID-19. 
Methods: The included data were provided from Web 
of Science, Cochrane, PubMed, and Scopus which are 
extracted from the published studies in English until 
April 2nd, 2020 that contained data on the risk of COV-
ID-19 in pregnancy.  
SUMMARY
Results: The early symptoms of patients with COV-
ID-19 were fever, cough, dyspnea, myalgia, and fa-
tigue; while production of sputum, headache, hemop-
tysis, and diarrhea were other symptoms which were 
less common. There is no evidence of vertical mater-
nal-fetal transmission in pregnant women with COV-
ID-19. 
Conclusions: The clinical findings in pregnant women 
with COVID-19 are not significantly different com-
pared to other patients, and pregnant women with 
COVID-19 are not at a higher risk of developing criti-
cal pneumonia compared to non-pregnant women. Al-
though, there has been no sign of vertical infection in 
infants, but maternal infection can cause serious prob-
lems such as preterm labour and fetal distress.
Keywords: COVID-19, pregnancy, SARS, neonates, 
coronavirus.
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CoV, genetic features of SARS-CoV-2 is found to 
be more similar to bat-SL-CoVZC45 and bat-SL-
CoVZXC21 which are SARS-like coronaviruses 
derived from the bat [4]. 
First identified in December 2019, COVID-19 be-
came an epidemic in Wuhan, Hubei Province, 
China [5]. Based on the World Health Organiza-
tion, 159 countries and regions have been affected 
between 31 December 2019 and 17 March 2020 [6]. 
Moreover, 184,976 cases were confirmed within 
this period with 7,529 deaths [6]. Since there  are 
suggestions regarding similarity  about the patho-
genesis of COVID-19 and SARS-CoV-1, the poten-
tial risk of vertical maternal-fetal transmission of 
COVID-19 may be as low as SARS-CoV-1 [7]. Vi-
ral infections such as SARS, MERS, and influenza 
have been related to the adverse pregnancy out-
comes [8-10]. To reduce fetal rejection, some phys-
iological changes happen in pregnant women for 
reducing immune responses [11]. Therefore, preg-
nant women may be at a higher risk of complica-
tions after COVID-19 infection. 
Multiple studies concerned about the effects of 
COVID-19 on pregnancy. Thus, this review aims 
to summarize the symptoms and possible risks 
of COVID-19 infection in pregnant women. We 
also provide a summary of studies as of April-
2nd, 2020on complications in fetuses or neonates 
whose mothers were infected with COVID-19. 
Data sources
The included data were provided from Web of Sci-
ence, Cochrane, PubMed, and Scopus which were 
extracted from the published studies in English 
until 2 April 2020 that contained data on the risk of 
COVID-19 in pregnancy with the following medi-
cal cases heading terms and/or text words: preg-
nancy, pregnancy outcomes, pregnant women, 
COVID-19, vertical transmission, and 2019-nCoV.
SARS-CoV-1 and pregnancy
Wong et al. [10] reported that the SARS tests  on 
neonates who were born to mothers with SARS 
were negative; however, out of seven pregnant 
women with SARS who were in the first trimester, 
four patients had a spontaneous miscarriage. In 
addition, out of five pregnant women with SARS 
who were after 24 weeks, four patients under-
went preterm delivery, and intrauterine growth 
restriction was observed despite women’s recov-
ery before delivery [10]. Another investigation on 
the effect of SARS-associated coronavirus among 
five neonates who were born to pregnant wom-
en with SARS during the outbreak in Hong Kong 
showed that all performed tests, including viral 
cultures, reverse transcriptase-polymerase chain 
reaction, and paired serologic titers were negative 
in those infants [12]. However, one preterm neo-
nates developed jejunal perforation shortly after 
birth, and another one suffered from ileal per-
foration and necrotizing enterocolitis [12]. Five 
pregnant women who were infected with SARS 
in their second or third trimester delivered their 
neonates with no evidence of SARS infection [13]. 
Stockman et al. also reported that samples of cord 
blood and placenta of one patient were negative 
for antibodies to SARS-CoV while her serum sam-
ples were positive at the time of delivery [14]. Fur-
thermore, breast milk samples, that were tested 
on days 12 and 30 of postpartum, were negative 
for the antibodies. The reverse transcription-poly-
merase chain reaction was also negative for viral 
RNA in stool samples of the neonates [14]. 
MERS-CoV and pregnancy
MERS-CoV infection clinical presentations vary 
from asymptomatic infection to more serious 
forms such as, acute respiratory distress syn-
drome, multi-organ failure, septic shock, and 
even death [15-18]. The disease shows nonspecif-
ic symptoms at the early stages, including head-
aches, malaise, low-grade fever, chills, myalgia, 
nonproductive cough, and dyspnea [19, 20]. Sim-
ilar to SARS-CoV, patients infected by MERS-
CoV may also suffer from some gastrointestinal 
symptoms which include abdominal pain, ano-
rexia, nausea, vomiting, and diarrhea [18]. Since 
acute respiratory distress syndrome occurs more 
frequently in MERS patients rather than patients 
with SARS, the mortality rate of MERS-CoV pa-
tients was higher (~36%) than SARS patients 
(~10%) [21].
A study indicated that one pregnant woman in-
fected by MERS-CoV presented with respiratory 
failure and admitted to ICU,delivered a healthy 
infant [22]. Another investigation demonstrated 
that all five pregnant women with MERS-CoV 
required ICU care; one women delivered a still-
born infant at 34 weeks and another infant died 
4 hours after delivery [8]. One pregnant woman 
whose polymerase chain reaction test was posi-
tive for MERS-CoV presented an abrupt vaginal 
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bleeding; results of several tests were all negative 
for MERS-CoV, indicating that this woman fully 
recovered from MERS without transmitting the 
infection to her baby [23].
Clinical and laboratory characteristics of pregnant 
women with COVID-19 infection
Huang et al. reported that the early symptoms 
of patients with COVID-19 were fever, cough, 
dyspnea, myalgia, and fatigue [24]. Production 
of sputum, headache, hemoptysis, and diarrhea 
were other less common symptoms [24]. Howev-
er, some patients did not show at first any signs 
of fever [24, 25]. Another study also reported that 
fever and cough were the most common symp-
toms of pneumonia onset in patients with COV-
ID-19 [26]. Wan et al. study on 135 patients with 
COVID-19 have indicated that fever, cough, and 
fatigue were the most common symptoms and 
chest CT images of all patients showed bilateral 
ground-glass opacity or patchy shadows in the 
lungs [25]. Ground-glass opacity has been report-
ed to be the most frequent early finding in chest 
CT images of 15 pregnant women with COVID-19 
[26]. 
In a study on three pregnant patients with con-
firmed COVID-19 infection, fever has been ob-
served as a symptom; while, there were no signs 
of significant lymphocytopenia or leukopenia 
[27]. Chen et al. observed that patients had de-
creased lymphocyte count and increased hyper-
sensitive C reactive protein [28]. Consolidations 
and crazy paving pattern are two other findings 
which were observed with the progression of 
COVID-19 infection [26]. Zhu et al. observed that, 
in addition to cough and fever, diarrhea occurred 
in one patient out of nine patients [29]. Notable, 
in Liu et al. study, lymphocytopenia has been con-
sidered as the most frequent abnormal findings in 
laboratory tests [26]. Some other clinical charac-
teristics have been observed in pregnant women 
with COVID-19 infection, including myalgia, sore 
throat, malaise, lymphocytopenia, and increased 
concentrations of aminotransferase [30]. Liu et al. 
found that leukocytosis, lymphopenia, increased 
neutrophil ratio, and initial normal body temper-
ature were more common in 41 pregnant women 
with COVID-19 who were clinically-diagnosed or 
laboratory-confirmed compared to non-pregnant 
patients [31]. They indicated that it is more com-
mon for some pregnant women to have mixed or 
complete consolidations compared to non-preg-
nant patients. Whereas, ground-glass opacity oc-
curred less frequently in the pregnant group com-
pared to non-pregnant group [31]. Interestingly, 
Liu et al. noted that the initial identification of 
pregnant women with COVID-19 infection may 
be more challenging due to their atypical clini-
cal findings [31]. Collectively, these studies have 
suggested that clinical characteristics of pregnant 
women with COVID-19 infection are similar to 
non-pregnant patients [27, 30, 32]. 


























≥ 37 ** 4 4 1 - 1 1 - 5 7 [32]
9 26-40 36 - 39+4 4 7 / 6 2 3 1 1 2 5 6 [30]
9 *** 30 31-39 5 9 - - 1 - 1 - - [29]
3 - - - 1 / 2 - - - - - 0 - [27]
16 - 37.9 ± 1.6 - - - - - - - - - [33]
41 **** 22-42 - 15 16 / 14 5 - 0 - - 25 27 [31]
7 29-34 37- 41+2 1 6 - - 1 - - - 7 [38]
* Age ranges belong to pregnant women who received epidural anesthesia and general anesthesia, respectively.
** Gestational ages belong to 14 patients out of 17 pregnant women. The three other women gestational age was less than 37 weeks. 
*** The authors reported the first symptoms in pregnant women and some symptoms probably haven’t been reported.
**** The number of cases include both laboratory-confirmed and clinically-diagnosed patients.
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What problems do the COVID-19 cause for pregnant 
women and their delivery?
As a retrospective study reported, there have been 
no significant differences in blood loss during the 
delivery (cesarean section) of 16 pregnant women 
with COVID-19 infection and 45 pregnant women 
without COVID-19 infection [33].  CT images that 
were taken before and after delivery of 11 preg-
nant women with COVID-19 infection demon-
strated that delivery did not lead to the pneu-
monia aggravation [26]. Moreover, other symp-
toms of the patients did not aggravate because 
of pregnancy or childbirth [26]. Liu et al. study 
indicated that all of 15 pregnant patients recov-
ered from COVID-19 pneumonia; although, some 
of them did not receive antiviral agents [26]. Chen 
et al. demonstrated that 17 pregnant women with 
COVID-19 delivered their babies safely through 
cesarean section with epidural or general anes-
thesia [32]. They also reported that intraoperative 
hypotension has occurred in 12 patients out of 14 
patients who received epidural anesthesia [32]. 
How COVID-19 affects the neonates who were born 
to women with COVID-19 infection?
There were no differences between birth weight, 
fetal distress, neonatal asphyxia, and preterm 
birth of the neonates who were born to women 
with or without COVID-19 [33]. Assessments 
of the placentas, that were delivered from preg-
nant women with confirmed COVID-19 infection, 
demonstrated different degrees of fibrin deposi-
tions both around and inside the villi, as well as 
increased local syncytial nodules. Data showed 
that one of the placentas had severe infarction 
and another one presented aconcurrent chorion-
ic hemangioma morphology. Meanwhile, none of 
the three placentas showed pathological changes 
in chorioamnionitis and villitis [27]. Records of 
15 pregnant women with COVID-19 indicated 
that there were no neonatal death, neonatal as-
phyxia, and stillbirth [26]. Another study showed 
that three out of 17 neonates who were born to 
women with COVID-19 were premature; howev-
er, no death or neonatal asphyxia were reported 
[32]. Zhu et al. found that six out of ten neonates 
who were born to women with COVID-19 were 
premature and Pediatric Critical Illness Score 
(PCIS) of six neonates were less than 90 [29]. They 
reported that perinatal infection with COVID-19 
may lead to some problems, including premature 
labour, thrombocytopenia, which is accompanied 
by abnormal liver function, fetal distress, respira-
tory distress, and death [29]. Chen et al. conclud-
ed that 1-min and 5-min Apgar scores of neonates 
born to women with COVID-19 were 8-9 and 
9-10, respectively [30]. Wang et al. also reported 
that a pregnant woman with COVID-19 delivered 
an infant with an uneventful postpartum and ne-
onatal course [34]. As studies investigated, all of 
the samples collected from neonates who were 
delivered by women infected with COVID-19 
were negative for COVID-19 nucleic acid [34]. 
Altogether, these findings suggest that there is 
no evidence of vertical transmission in pregnant 
women with COVID-19. 
What should be considered when administering 
medicines for pregnant women?
Based on interim guidance provided by the World 
Health Organization on 13 March 2020, no specif-
ic anti-COVID-19 treatments are recommended. 
However, several clinical trials are investigating 
potential antivirals medications  to treat COV-
Table 2 - Neonatal outcomes in infants who were born to women with COVID-19.
Cases Severe asphyxia Death 1-min/5-min Apgar scores Low birth weight Premature delivery Reference
11 0 0 8 / 9 - - [26]
17 0 0 9 / 10 0 3 [32]
9 0 0 8-9 / 9-10 2 4 [30]
7 0 0 8-9 / 9-10 0 - [38]
3 - 0 - 1 * 1 [27]
10 - 1 7-10 / 8-10 2** 6 [29]
*Authors reported that one premature infant was transferred to the neonatology department due to the low birth weight but we are not aware 
whether the rest of the neonates had a low birth weight or not. 
**Two infants were small-for-gestational-age and 1 was a large-for-gestational-age. 
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ID-19 [35]. Chloroquine and remdesivir (GS-5734) 
are two antiviral drugs that have shown prom-
ising inhibitory effects on SARS-CoV-2 replica-
tion in cell culture [36]. Chloroquine has shown 
adverse effects on the fetal development [37]. 
Meanwhile, Zhou et al. suggested that hydroxy-
chloroquine is a better potential therapeutic agent 
compared to chloroquine because of its safety 
profile in pregnant women [37]. It is observed that 
a higher dose of carbetocin or carboprost trometh-
amine has been used during cesarean section of 
pregnant women with COVID-19 compared to 
women without COVID-19 for treating uterine 
contraction fatigue. Thus, it is suggested that 
prophylactic administration of uterotonic drugs 
may lead to the less postpartum hemorrhage in 
women [33]. 
n CONCLUSIONS
There are a few studies concerning with the effects 
of COVID-19 on pregnant women and their neo-
nates. However, there is not enough evidence to 
draw a definitive conclusion. As the COVID-19 is 
spreading further all over the world, more studies 
are needed to be performed on the pregnant pa-
tients and their neonates. We discussed the clini-
cal, laboratory, and radiological characteristics of 
pregnant women with COVID-19 infection and 
concluded: (1) clinical findings in pregnant wom-
en with COVID-19 are not significantly different 
compared to other patients; (2) pregnant women 
with COVID-19 are not at a significantly higher 
risk of developing critical pneumonia compared 
to non-pregnant women; (3) and there has been 
no sign of vertical infection in infants, but mater-
nal infection can cause serious problems such as 
preterm labour and fetal distress.
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